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ABSTRACT  
Benzimidazole pharmacophore possess broad class of curative properties like 
anthelmintic, antiulcer, antihypertensive, anticancer, etc. In view of this reason 
benzimidazole derivatives synthesis gained vital significance in recent years. In 
this investigation, a series of novel substituted benzimidazole derivatives having 
furan appendage at 2nd position and alkyl/aryl appendage at 1st position were 
synthesized by using appropriate procedures. All the compounds synthesized 
were characterized by physically (Rf values, Melting point, Molecular weight, 
Molecular formula) and were characterized by spectral data (1H-NMR, 13C-NMR, 
IR and Mass spectra). All the synthesized compounds were screened for molecular 
docking studies on human gamma-tubulin protein to find out the binding 
interaction at the target active site. Molecular docking studies at human gamma-
tubulin protein states that the compound 4b showed good binding affinity (-8.98 
kcal/mol) in comparison to the reference compound Albendazole (-8.47 
kcal/mol). 
INTRODUCTION
In the current drug discovery research, heterocyclic 
ring containing drug molecules gained much more 
importance. Heterocyclic compounds take over 
various fields such as organic chemistry, medicinal 
chemistry, biochemistry, agricultural sciences. 
Heterocyclic compounds chemistry played a 
fundamental role in the metabolism of most of all 
living cells[1]. Among different classes of 
heterocyclic compounds, benzimidazole is the key 
scaffold which can be found in many active 
pharmaceutical ingredients. The benzimidazoles 
contain a phenyl ring fused to an imidazole ring, as 
indicated in the structure for benzimidazole. 
Currently used antiulcer drugs- Omeprazole, 
Lansoprazole, Pantoprazole, Rabeprazole; 
anthelmintic drugs- Albendazole, Mebendazole, 
Thiabendazole possessing benzimidazole moiety 
were mentioned (Fig. 1).  
Fig. 1: Commonly used benzimidazole pharmacophore containing drugs 
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Benzimidazole nucleus containing compounds or 
derivatives possess broad range of therapeutic 
activities like anthelmintic, antiviral, antiulcer, 
antihypertensive, anticancer, etc. In recent years 
benzimidazole derivatives gained much more 
importance in organic synthesis[2,3]. Diverse 
synthetic approaches were reported in the 
literature for benzimidazole ring synthesis. o-
phenylenediamine was condensed with various 
aldehydes using solid-supported catalyst[4], 
transition metal catalysts like Sc(OTf)3[5], 
Yb(OTf)3[6], FeCl3.6H2O[7], In(OTf)3[8], Cobalt 
complexes[9] and also in the presence of different 
oxidizing agents like air[10], Pb(OAc)4[11], Sulphamic 
acid[12], MnO2[13], Oxone[14], Iodine[15], H2O2–HCl[16], 
DDQ[17] etc. Other approach states carboxylic acids 
condensed with o-phenylenediamine in the 
presence of acid catalysts[18]. 
Pharmaceutical, veterinary and agrochemical 
products developed with benzimidazole moiety 
includes Albendazole, mebendazole, thiabendazole, 
astemizole, lansoprazole, omeprazole, 
pantoprazole, etc[9]. Phillip’s method[20], involves in 
the condensation of o-phenylenediamine with 
carboxylic acids or its derivatives, including heating 
the reagents together in the presence of 
concentrated HCL (Scheme 1), is the most common 
synthetic method for preparation of a wide range of 
benzimidazoles. 
In the present work a series of novel substituted 
benzimidazole derivatives having furan appendage 
at 2nd position and alkyl/aryl appendage at 1st 
position were synthesized by using appropriate 
procedures. All the synthesized compounds were 
characterised and tested for molecular docking 
studies. 
MATERIALS AND METHODS 
All the chemicals and reagents for the synthesis of 
N-substituted-2-(furan-3-yl)-1H-benzimidazole 
derivatives were procured from commercial 
suppliers of Merck grade. Completion of the 
reaction was monitored by thin layer 
chromatography with the help of E.Merck grade 
precoated silica gel 60-GF-254 TLC plates. Melting 
points were determined by using electrical melting 
point apparatus and those were uncorrected. By 
using KBr pressed pellet technique, IR spectra of 
the compounds were recorded in Bruker FT-IR 
analyzer spectrophotometer. Chemical shifts in 
ppm of 1H-NMR spectra and 13C-NMR were 
recorded on Bruker-AMX-400MHz 
spectrophotometer using deuterated dimethyl 
sulfoxide (DMSO) solvent and tetramethylsilane 
(TMS) as internal standard. Mass spectra of the 
compounds were recorded on an Agilent LC-MSD-
1200 mass spectrometer. All the novel synthesized 
compounds were evaluated for molecular docking 
studies on β-tubulin protein to find out the binding 
interaction at the target site. 
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Scheme 2: Scheme of synthesis of N-substituted-2-(furan-3-yl)-1H-benzimidazoles 
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Lemon Juice Preparation[21] 
Lemon botanically Citrus limonium, Citrus 
aurantium and Citrus indica are the species of citrus 
family. Presence of citric acid and ascorbic acids in 
lemon juice acts as acid catalyst in organic 
reactions. Fresh lemons were purchased, obtained 
the juice by making them into pieces and with the 
help of juicer. Juice was further filtered through 
filter paper and clear solution of juice was used as 
reaction catalyst. The pH of the extracted lemon 
juice was found to be 2.4. 
Step-I: Procedure for Synthesis of 2-(furan-3-yl)-
1H-benzimidazole (3)[21] 
To a mixture of o-phenylenediamine (0.02 mol) and 
furfural (0.02 mol) add 6-8ml of 1:1 V/V lemon 
juice: water mixture. The reaction mixture was 
refluxed for 3-4 hrs at 80°C. The completion of the 
reaction was confirmed by TLC (using Silica Gel - G 
stationary phase and ethylacetate:hexane, 1:2 V/V 
as mobile phase). The reaction mixture was 
quenched with cold water and stirred continuously 
until free flowing solid was obtained. The resulting 
solid was filtered, air dried and purified by 
recrystallization from 95% ethanol to get pure 
product.  
Step-II: Procedure for synthesis of N-
substituted-2-(furan-3-yl)-1H-benzimidazole 
(4a-4e)[22]  
To a mixture of 2-(furan-3-yl)-1H-benzimidazole 
(3) (0.02 mol) and alkyl/aryl halide (0.02 mol) in 
10ml of THF, little quantity of sodium hydride (2 g) 
was added. The resulting mixture was stirred for 8-
12 hrs at 40-50°C. The completion of the reaction 
was confirmed by TLC (using Silica Gel - G 
stationary phase and ethylacetate: hexane, 1:2 V/V 
as mobile phase). Excess solvent was removed by 
distillation. The crude product was washed with 
cold water, extracted with ethyl acetate and finally 
purified by recrystallization from 95% ethanol to 
get pure product.  
Spectral Data  
N-benzyl-2-(furan-3-yl)-1H-benzimidazole (4a): 
IR [KBr, cm-1]: 3064.24 (=CH stretch), 2963.18 (-CH 
stretch), 1628.46 (C=N stretch), 1567.18 (C=C 
stretch), 1329.09 (C-N stretch), 1094.33 (C-O 
stretch). 1H-NMR (400 MHz, DMSO-D6) δ: 7.914 (1H, 
s, Furan C2-H), 6.845-7.017 (1H, d, Furan C4-H), 
7.215-7.321 (1H, d, Furan C5-H), 7.339-7.505 (5H, 
m, Phenyl), 7.611-7.698 (2H, dd, benzimidazole C5-
H & C6-H), 7.892-7.917 (2H, dd, benzimidazole C4-H 
& C7-H), 5.523 (2H, s, -CH2-phenyl). 13C-NMR (100 
MHz, DMSO-D6) δ: 158.65, 146.65, 143.97, 138.64, 
136.31, 133.08, 129.07, 128.11, 125.47, 124.74, 
122.88, 119.34, 117.36, 107.37, 53.48. ESI-MS: m/z 
(M+) 274. 
N-benzoyl-2-(furan-3-yl)-1H-benzimidazole 
(4b): IR [KBr, cm-1]: 3019.88 (=CH stretch), 1709.44 
(C=O stretch), 1633.94 (C=N stretch), 1555.72 (C=C 
stretch), 1309.65 (C-N stretch), 1086.12 (C-O 
stretch). 1H-NMR (400 MHz, DMSO-D6) δ: 6.882-
7.200 (1H, d, Furan C4-H), 7.219-7.478 (5H, m, 
Phenyl), 7.506-7.526 (2H, dd, benzimidazole C5-H & 
C6-H), 7.742-7.747 (1H, d, Furan C5-H), 7.880-7.899 
(2H, dd, benzimidazole C4-H & C7-H), 8.069 (1H, s, 
Furan C2-H). 13C-NMR (100 MHz, DMSO-D6) δ: 
165.73, 145.35, 140.21, 138.71, 136.54, 134.11, 
133.08, 131.92, 130.31, 128.64, 126.45, 123.10, 
116.76, 113.28, 108.59. ESI-MS: m/z (M+) 288. 
N-(o-hydroxyphenyl)-2-(furan-3-yl)-1H-
benzimidazole (4c): IR [KBr, cm-1]: 3423.29 (OH 
stretch), 3070.51 (=CH stretch), 1608.26 (C=N 
stretch), 1528.80 (C=C stretch), 1318.47 (C-N 
stretch), 1079.09 (C-O stretch). 1H-NMR (400 MHz, 
DMSO-D6) δ: 6.860-7.127 (1H, d, Furan C4-H), 
7.239-7.280 (4H, m, Phenyl), 7.511-7.539 (2H, dd, 
benzimidazole C5-H & C6-H), 7.746-7.767 (1H, d, 
Furan C5-H), 7.886-7.900 (2H, dd, benzimidazole C4-
H & C7-H), 8.095 (1H, s, Furan C2-H), 5.323 (1H, s, 
OH). 13C-NMR (100 MHz, DMSO-D6) δ: 149.26, 
146.32, 143.18, 141.08, 138.64, 135.19, 129.71, 
127.84, 126.33, 124.55, 122.07, 120.38, 118.47, 
115.81, 112.42, 107.66. ESI-MS: m/z (M+) 276. 
N-acetyl-2-(furan-3-yl)-1H-benzimidazole (4d): 
IR [KBr, cm-1]: 3044.35 (=CH stretch), 2966.25 (-CH 
stretch), 1715.08 (C=O stretch), 1624.22 (C=N 
stretch), 1549.64 (C=C stretch), 1333.60 (C-N 
stretch), 1077.15 (C-O stretch). 1H-NMR (400 MHz, 
DMSO-D6) δ: 7.708 (1H, s, Furan C2-H), 6.964-7.108 
(1H, d, Furan C4-H), 7.402-7.499 (1H, d, Furan C5-H), 
7.227-7.318 (2H, dd, benzimidazole C5-H & C6-H), 
7.542-7.609 (2H, dd, benzimidazole C4-H & C7-H), 
2.548 (3H, s, -COCH3). 13C-NMR (100 MHz, DMSO-
D6) δ: 167.29, 145.19, 142.37, 138.26, 135.97, 
133.47, 128.47, 124.08, 116.37, 113.48, 108.72, 
23.67. ESI-MS: m/z (M+) 226. 
N-ethyl-2-(furan-3-yl)-1H-benzimidazole (4e): 
IR [KBr, cm-1]: 3056.97 (=CH stretch), 2989.27 (-CH 
stretch), 1633.83 (C=N stretch), 1569.55 (C=C 
stretch), 1348.73 (C-N stretch), 1081.86 (C-O 
stretch). 1H-NMR (400 MHz, DMSO-D6) δ: 7.816 (1H, 
s, Furan C2-H), 6.817-6.907 (1H, d, Furan C4-H), 
7.195-7.207 (1H, d, Furan C5-H), 7.310-7.399 (2H, 
dd, benzimidazole C5-H & C6-H), 7.566-7.611 (2H, 
dd, benzimidazole C4-H & C7-H), 4.156-4.408 (2H, q, 
-CH2CH3), 1.391-1.529 (3H, t, -CH2CH3). 13C-NMR 
(100 MHz, DMSO-D6) δ: 156.09, 145.31, 141.20, 
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137.97, 134.75, 129.46, 125.34, 119.66, 112.28, 
107.36, 41.67, 18.71. ESI-MS: m/z (M+) 212. 
Molecular docking studies  
Molecular docking studies on human gamma 
tubulin protein[23]. The ligand molecules were 
designed, and the structures were analyzed by 
using ChemDraw Ultra 12.0. Three-dimensional 
(3D) structure coordinates were prepared using 
Chem3D ultra 12.0. Nonpolar hydrogen atoms were 
merged, and the rotatable bonds were set by using 
Auto-Dock 4.2 Tools. The crystal structure of human 
gamma-tubulin (PDB ID: 1Z5V) was selected from 
the PDB (www.rcsb.org/pdb) and was edited by 
removing the heteroatoms, adding C terminal 
oxygen. Polar hydrogens and Gasteiger charges 
were added after merging non-polar hydrogens. 
The grid map was centered at the active pocket of 
the protein by AutoGrid4. It is the grid map, which 
was centered at the active pocket of the protein. 
Automated docking was used to determine the 
orientation of inhibitors bound in the active site. A 
Lamarckian genetic algorithm method, 
implemented in the program AutoDock 4.2, was 
employed to identify appropriate binding modes 
and conformations of the ligand. The Lamarckian 
genetic algorithm methods were applied for 
minimization, using default parameters. Binding 
energy, number of H-bonds, H-bond length and 
amino acid residues interacted were recorded in 
each ligand confirmations.  
RESULTS AND DISCUSSION 
N-substituted-2-(furan-3-yl)-1H-benzimidazole 
derivatives were synthesized using the appropriate 
synthetic procedure (Scheme 2) i.e. reaction of o-
phenylenediamine (1) and furfural (2) in presence 
of lemon juice and water gives 2-(furan-3-yl)-1H-
benzimidazole (3). Further the title compounds 1-
substituted-2-substituted benzimidazole 
derivatives (4a-4e) were prepared by the reaction 
of 2-(furan-3-yl)-1H-benzimidazole (3) with 
different alkyl/ aryl halides in presence of sodium 
hydride using THF as solvent. The progress of the 
reaction was monitored by TLC. Finally, the 
reaction mixture was poured onto the crushed ice 
and then recrystallized from ethanol. Melting points 
were determined in open capillaries and were 
uncorrected. IR spectra of the compounds were 
recorded in KBr discs on Bruker FT-IR analyzer 
spectrophotometer. 1H-NMR spectra were recorded 
on Bruker-400MHz spectrophotometer and 13C-
NMR spectra were recorded on Bruker-AMX-
400MHz spectrophotometer. Mass spectra of the 
compounds were recorded on an Agilent LC-MSD-
1200 mass spectrometer. Physical characterization 
data of all the synthesized compounds were given 
in Table I. 
Table I: Physical characterization data of the synthesized compounds 4a-4e 
Compd. R m.p. (ºC) 
Molecular 
formula 
m.w. % yield Rf value  
4a 
H2
C
 
226-228 C18N2H14O 274 79.48 0.54 
4b 
C
O
 
212-214 C18H12N2O2  288 70.86 0.61 
4c 
HO  
240-242 C17H12N2O2 276 80.26 0.65 
4d 
CH3C
O
 
230-232 C13H10N2O2  226 75.47 0.58 
4e CH3
H2
C  
202-204 C13H12N2O  212 73.58 0.51 
The molecular docking of ligand molecules with 
human gamma-tubulin revealed that most of the 
molecules exhibited the bonding with one or the 
other amino acids in the active pockets. 
Theoretically all the ligand molecules showed 
encouraging binding energy. Among the five 
molecules, docking of human gamma-tubulin 
revealed that their binding energy were -6.89, -8.98, 
-8.66, -8.35 and -7.88 kcal/mol respectively. 
Molecules 4b and 4c showed significant binding 
affinity towards the active pocket with good binding 
energy, ligand efficiency and hydrogen bonding, 
those can be considered as good inhibitor of human 
gamma-tubulin. The binding energy values revealed 
that the compounds 4b and 4c showed good binding 
affinity towards the human gamma-tubulin and the 
computed values were depicted in the Table II. The 
interaction of Albendazole at the active site of the 
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human gamma-tubulin has showed binding energy 
of -8.47 kcal/mol and the amino acids interacted 
were Thr131, Gly132, Gly129, Val160, Ser126 and 
Cys12. The 3D structure of human gamma-tubulin, 
docking complex of human gamma-tubulin protein-
1Z5V against Albendazole, compound 4b and 
compound 4c was shown in the Fig. 2. The 
compound 4b shown promising binding affinity i.e. -
8.98 kcal/mol and the amino acids interacted were 
Phe208, Cys12, Ser126, Ala128, Val157, Pro159, 
Asn190. 
Table II: Binding energy and amino acid residues interacted by the compounds 4a-4e with the 
target β-tubulin protein PDB ID – 1Z5V 
Compound 
Binding energy 
(kcal/mol) 
No. of H 
bonds 
H-bond length 
Amino acid residues 
interacted 
Albendazole -8.47 8 
2.04, 2.27, 2.19, 3.35, 
2.35, 5.03, 4.93, 4.32 
Thr131, Gly132, Gly129, Val160, 
Ser126, Cys12 
4a -6.89  5 3.16, 2.85, 4.31, 2.64, 3.68 
Ala128, Gly132, Val157, Pro159, 
Ser126, Phe208 
4b -8.98  9 
2.74, 2.77, 3.73, 1.90, 
4.97, 4.30, 4.11, 3.18, 5.70 
Phe208, Cys12, Ser126, Ala128, 
Val157, Pro159, Asn190 
4c -8.66  7 
4.17, 2.68, 2.49, 3.85, 
2.82, 4.81, 3.28 
Glu62, Gly132, Gly130, Val164 
4d -8.35  7 
3.62, 5.37, 3.61, 3.58, 
3.90, 2.60, 2.84 
Cys12, Val157, Phe208, Asn190 
4e -7.88 5 3.56, 2.41, 5.61, 4.22, 3.22 Val160, Gly131, Phe208, Pro159 
 
Fig. 2: Molecular docking studies at β-tubulin protein (PDB ID- 1Z5V). 
a) Structure of β-tubulin protein PDB ID- 1Z5V.  
b) Docking complex β-tubulin protein (PDB ID- 
1Z5V) with Albendazole.  
c) Docking complex of β-tubulin protein (PDB ID- 
1Z5V) with compound 4b.  
d) Docking complex of β-tubulin protein (PDB ID- 
1Z5V) with compound 4c  
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CONCLUSION 
A facile method under mild conditions has been 
developed for the synthesis of the title compounds. 
In this investigation various novel benzimidazole 
derivatives (4a-4e) possessing furan appendage at 
2nd position and alkyl/aryl appendage at 1st position 
were developed. Characterization of the compounds 
was done by physically and spectrally. Among the 
synthesized compounds N-(o-hydroxyphenyl)-2-
(furan-3-yl)-1H-benzimidazole (4c) gives high 
percentage yield. Molecular docking studies at 
human gamma-tubulin protein states that the 
compound 4b and 4c showed good binding affinity 
(-8.98 & -8.66 kcal/mol) in comparison to the 
reference compound Albendazole (-8.47 kcal/mol). 
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